Flerie AB (publ) (FLERIE) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to FLIRI's Q3 report presentation with me, Ted Fjellman, and our CFO Cecilia Schiele. We're very excited to tell you about the advancing life science innovations from our portfolio and also to help explain our unique share redemption scheme that was introduced with our IPO three months ago. Before we do that, the usual disclaimer. And let me start before we go into the details about the Q3 report and just reminding those of you who may not know us so well of our way of working and also the fact that we have been around since 2011 and have a proven track record of 14% IRR per year. Just a reminder, we are a life science investment company. We're very active investors investing in a diversified portfolio of 29 companies using these four pillars on the left hand side, always taking a board seat and through that being active, also working with the CEO management teams on product roadmaps and also the expansion of their often platform technologies that are very widely applicable. And of course, building up this famous Fleary and Peers peer-to-peer network that we've had for many years now, really valued by the CEOs who get to exchange with each other and really learn from each other. And last but not least, the collaborations and the synergies that we try to establish to advance our both products and services on the market the most famous case of that being north x biologics than our manufacturing powerhouse not unlike the very early days of recifarm that our chairman thomas eldred built up we're now building up northex biologics and all many of our companies are working with northex let's move on to the q3 report details So, we have an active portfolio approach and it is delivering results. So, today I'll talk a little bit about the syndication a...